WFD Ventures Portfolio Company Gains FDA Approval for Novel Cancer Treatment

First ever medical device therapy indicated as an alternative to chemotherapy for cancer

NEW YORK, April 18, 2011 - WFD Ventures, a venture capital firm focused on breakthrough medical
products, announced the achievement of an important milestone for its
portfolio company, NovoCure. The U.S. Food and Drug Administration (FDA)
granted NovoCure approval to market its treatment for glioblastoma multiforme
(GBM). WFD Ventures began working with NovoCure's founder, Dr. Yoram Palti,
in 2003 and made its initial investment in 2004 to support the first-in-man
clinical trials.

"The FDA approval of the NovoTTF device is the culmination of ten years
of research, development and clinical trials conducted by an exceptional team
of scientists, engineers, and clinicians and built on the original insights
of our founder and CTO, Yoram Palti, M.D., Ph.D.," said William F. Doyle, WFD
Ventures' Managing Partner. "We look forward to bringing this device to
recurrent GBM patients and their families and developing NovoTTF therapy for
a range of additional solid tumor cancers."

"In the beginning, very few people could understand how our technology
might treat cancer gently and effectively," said Asaf Danziger, NovoCure's
Chief Executive Officer. "Bill Doyle was our first supporter, and he and his
team at WFD Ventures have worked with us hand in hand every day since 2003 to
make a difference for cancer patients."

About WFD Ventures

WFD Ventures seeks to partner with medical device and healthcare
technology companies that have the potential to make a major impact on
patient care. The principals of WFD have extensive experience commercializing
medical technologies and work with entrepreneurs, doctors and scientists to
improve medical outcomes and maximize the financial potentials of their
innovations. Please visit www.wfdventures.com.

About NovoCure

NovoCure Limited is a private oncology company pioneering a novel therapy
for solid tumors. NovoCure's worldwide headquarters is located in the Jersey
Isle. NovoCure's U.S. operations are based in Portsmouth, NH and the
company's research center is located in Haifa, Israel. For additional
information about the company, please visit www.novocure.com.

CONTACT: Tim Langloss, +1-212-767-7502

.